FLT3 and acute myeloid leukemia: The MRD status could also play another important clinical role in guiding preemptive therapy in patients with FLT3-mutated AML, as there are now available several FLT3 inhibitors, such as gilteritinib and quizartinib, or other multikinase-inhibitors that also target FLT3, such as midostaurin and sorafenib [113,114].